CXCL12 and neoplasm: The key finding of this study is that M2pep‐Cs NPs/Plerixafor NPs effectively inhibit the CXCL12–CXCR4 pathway, resulting in TAM reprogramming and enhanced immune recognition of GC cells, thereby suppressing tumor growth.